J&J says drug combo contains lung cancer from spreading for longer
duration
Send a link to a friend
[September 07, 2023]
(Reuters) - Johnson & Johnson said on Wednesday its combination
drug helped increase the duration of no progress in a type of non
small-cell lung cancer in patients.
The therapy met the main goals of the study that tested a combination of
antibody treatment Rybrevant and experimental drug lazertinib against
chemotherapy in patients with a more common mutation in EGFR protein
that causes rapid cell growth.
J&J's therapy was tested in patients in whom the disease progressed even
after they were treated with AstraZeneca's Tagrisso.
Rybrevant received approval in 2021 for only 2-3% of non small-cell lung
cancer (NSCLC) patients - a small subset that had a specific type of
mutation in EGFR protein.
J&J is also testing its combination treatment in a head-to-head study
with Tagrisso, and expects data from the trial by the end of this year.
If successful, the company expects the therapy to become a first-line
treatment for NSCLC patients with the mutation.
[to top of second column]
|
The Johnson & Johnson logo is displayed on a screen on the floor of
the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019.
REUTERS/Brendan McDermid/File Photo
Tagrisso generated over $5.4 billion
in 2022.
(Reporting by Leroy Leo in Bengaluru; Editing by Pooja Desai and
Shinjini Ganguli)
[© 2023 Thomson Reuters. All rights
reserved.]This material
may not be published, broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|